Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BeOne Medicines Ltd.BGNE · Entity 2168 | Director | June 05, 2024 | June 07, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BeOne Medicines Ltd.
Report date June 05, 2024 · Filed June 07, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 2,718,464 |
Reported balance
After 2024-06-05 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2024-06-05 · Grant · Acquired 16,341 · Balance 2,718,464 F1: Represents securities underlying restricted share units. The restricted share units shall become fully vested on the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting; provided, however, that all vesting shall cease if the director resigns from the board of directors or otherwise ceases to serve as a director, unless the board determines otherwise. Unvested securities are subject to accelerated vesting upon a change in control or certain termination events. The restricted share units were granted under the Company's Independent Director Compensation Policy, as amended. |
| Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.23 · Expires 2034-06-04 | Direct | 34,151 |
Reported balance
After 2024-06-05 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-06-05 · Grant · Acquired 34,151 · Balance 34,151 F2: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. Each American Depositary Share represents 13 ordinary shares. F3: The option shall become exercisable in full upon the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting; provided, however, that all vesting shall cease if the Reporting Person resigns from the board of directors or otherwise ceases to serve as a director, unless the board determines otherwise. Unvested securities are subject to accelerated vesting upon a change in control or certain termination events. The option was granted under the Company's Independent Director Compensation Policy, as amended. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents securities underlying restricted share units. The restricted share units shall become fully vested on the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting; provided, however, that all vesting shall cease if the director resigns from the board of directors or otherwise ceases to serve as a director, unless the board determines otherwise. Unvested securities are subject to accelerated vesting upon a change in control or certain termination events. The restricted share units were granted under the Company's Independent Director Compensation Policy, as amended.
F2: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. Each American Depositary Share represents 13 ordinary shares.
F3: The option shall become exercisable in full upon the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting; provided, however, that all vesting shall cease if the Reporting Person resigns from the board of directors or otherwise ceases to serve as a director, unless the board determines otherwise. Unvested securities are subject to accelerated vesting upon a change in control or certain termination events. The option was granted under the Company's Independent Director Compensation Policy, as amended.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 05, 2024 Filed Jun 7, 2024 20:58 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | GrantShare Option (Right to Buy) · Derivative | 34,151 | $0.00 Strike: $12.23 | $0.00 |
DisclosureSEC source: 0001651308-24-000060 · wk-form4_1717793874.xml · derivative · entry 2 Glazer Donald W. · CIK 0001660940 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,151 Underlying: Ordinary Shares · 34,151 shares Expires 2034-06-04 F2 · derivative.exercise_price: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. Each American Depositary Share represents 13 ordinary shares. F2 · shares: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. Each American Depositary Share represents 13 ordinary shares. F3 · derivative.exercise_date: The option shall become exercisable in full upon the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting; provided, however, that all vesting shall cease if the Reporting Person resigns from the board of directors or otherwise ceases to serve as a director, unless the board determines otherwise. Unvested securities are subject to accelerated vesting upon a change in control or certain termination events. The option was granted under the Company's Independent Director Compensation Policy, as amended. Read SEC document |
| June 05, 2024 Filed Jun 7, 2024 20:58 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | GrantOrdinary Shares | 16,341 | $0.00 | $0.00 |
DisclosureSEC source: 0001651308-24-000060 · wk-form4_1717793874.xml · nonDerivative · entry 1 Glazer Donald W. · CIK 0001660940 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,718,464 F1 · security: Represents securities underlying restricted share units. The restricted share units shall become fully vested on the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting; provided, however, that all vesting shall cease if the director resigns from the board of directors or otherwise ceases to serve as a director, unless the board determines otherwise. Unvested securities are subject to accelerated vesting upon a change in control or certain termination events. The restricted share units were granted under the Company's Independent Director Compensation Policy, as amended. Read SEC document |
| March 11, 2024 Filed Mar 13, 2024 21:04 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | GiftOrdinary Shares | 82,020 | $0.00 | $0.00 |
DisclosureSEC source: 0001651308-24-000023 · wk-form4_1710363830.xml · nonDerivative · entry 1 Glazer Donald W. · CIK 0001660940 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,702,123 F1 · price: Bona fide gifts of shares which are exempt from Section 16(b) of the Securities Exchange Act pursuant to Rule 16b-5. Read SEC document |
| June 15, 2023 Filed Jun 20, 2023 22:58 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | GrantShare Option (Right to Buy) · Derivative | 26,975 | $0.00 Strike: $16.41 | $0.00 |
DisclosureSEC source: 0001651308-23-000095 · wf-form4_168730187423688.xml · derivative · entry 2 Glazer Donald W. · CIK 0001660940 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,975 Underlying: Ordinary Shares · 26,975 shares Expires 2033-06-14 F2 · derivative.exercise_price: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. Each American Depositary Share represents 13 Ordinary Shares. F2 · shares: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. Each American Depositary Share represents 13 Ordinary Shares. F3 · derivative.exercise_date: The option shall become exercisable in full upon the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting; provided, however, that all vesting shall cease if the Reporting Person resigns from the board of directors or otherwise ceases to serve as a director, unless the board determines otherwise. Unvested securities are subject to accelerated vesting upon a change in control or certain termination events. The option was granted under the Company's Independent Director Compensation Policy, as amended. Read SEC document |
| June 15, 2023 Filed Jun 20, 2023 22:58 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | GrantOrdinary Shares | 12,922 | $0.00 | $0.00 |
DisclosureSEC source: 0001651308-23-000095 · wf-form4_168730187423688.xml · nonDerivative · entry 1 Glazer Donald W. · CIK 0001660940 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,784,143 F1 · security: Represents securities underlying restricted share units. The restricted share units shall become fully vested on the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting; provided, however, that all vesting shall cease if the director resigns from the board of directors or otherwise ceases to serve as a director, unless the board determines otherwise. Unvested securities are subject to accelerated vesting upon a change in control or certain termination events. The restricted share units were granted under the Company's Independent Director Compensation Policy, as amended. Read SEC document |
| June 22, 2022 Filed Jun 24, 2022 21:38 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | GrantShare Option (Right to Buy) · Derivative | 34,645 | $0.00 Strike: $11.98 | $0.00 |
DisclosureSEC source: 0001651308-22-000107 · wf-form4_165610668501437.xml · derivative · entry 2 Glazer Donald W. · CIK 0001660940 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,645 Underlying: Ordinary Shares · 34,645 shares Expires 2032-06-21 F2 · derivative.exercise_price: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. Each American Depositary Share represents 13 Ordinary Shares. F2 · shares: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. Each American Depositary Share represents 13 Ordinary Shares. F3 · derivative.exercise_date: The option shall become exercisable in full upon the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting; provided, however, that all vesting shall cease if the Reporting Person resigns from the board of directors or otherwise ceases to serve as a director, unless the board determines otherwise. Unvested securities are subject to accelerated vesting upon a change in control or certain termination events. The option was granted under the Company's Independent Director Compensation Policy, as amended. Read SEC document |
| June 22, 2022 Filed Jun 24, 2022 21:38 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | GrantOrdinary Shares | 16,692 | $0.00 | $0.00 |
DisclosureSEC source: 0001651308-22-000107 · wf-form4_165610668501437.xml · nonDerivative · entry 1 Glazer Donald W. · CIK 0001660940 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,771,221 F1 · security: Represents securities underlying restricted share units. The restricted share units shall become fully vested on the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting; provided, however, that all vesting shall cease if the director resigns from the board of directors or otherwise ceases to serve as a director, unless the board determines otherwise. Unvested securities are subject to accelerated vesting upon a change in control or certain termination events. The restricted share unites were granted under the Company's Independent Director Compensation Policy, as amended. Read SEC document |
| June 16, 2021 Filed Jun 21, 2021 20:39 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | GrantShare Option (Right to Buy) · Derivative | 17,498 | $0.00 Strike: $26.53 | $0.00 |
DisclosureSEC source: 0001651308-21-000123 · wf-form4_162430797209409.xml · derivative · entry 2 Glazer Donald W. · CIK 0001660940 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,498 Underlying: Ordinary Shares · 17,498 shares Expires 2031-06-15 F2 · derivative.exercise_price: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. Each American Depositary Share represents 13 Ordinary Shares. F2 · shares: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. Each American Depositary Share represents 13 Ordinary Shares. F3 · derivative.exercise_date: The option shall become exercisable in full upon the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting; provided, however, that all vesting shall cease if the Reporting Person resigns from the board of directors or otherwise ceases to serve as a director, unless the board determines otherwise. Unvested securities are subject to accelerated vesting upon a change in control or certain termination events. Read SEC document |
| June 16, 2021 Filed Jun 21, 2021 20:39 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | GrantOrdinary Shares | 7,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001651308-21-000123 · wf-form4_162430797209409.xml · nonDerivative · entry 1 Glazer Donald W. · CIK 0001660940 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,754,529 F1 · security: Represents securities underlying restricted share units. The restricted share units shall become fully vested on the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting; provided, however, that all vesting shall cease if the director resigns from the board of directors or otherwise ceases to serve as a director, unless the board determines otherwise. Unvested securities are subject to accelerated vesting upon a change in control or certain termination events. Read SEC document |
| June 03, 2021 Filed Jun 7, 2021 21:07 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | GiftOrdinary Shares | 7,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001651308-21-000106 · wf-form4_162310002440774.xml · nonDerivative · entry 1 Glazer Donald W. · CIK 0001660940 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,746,729 F1 · price: Bona fide gift of shares which is exempt from Section 16(b) of the Securities Exchange Act pursuant to Rule 16b-5. Read SEC document |
| June 01, 2021 Filed Jun 3, 2021 20:51 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | GiftOrdinary Shares | 69,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001651308-21-000100 · wf-form4_162275345321771.xml · nonDerivative · entry 1 Glazer Donald W. · CIK 0001660940 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,754,129 F1 · price: Bona fide gift of shares which is exempt from Section 16(b) of the Securities Exchange Act pursuant to Rule 16b-5. Read SEC document |
| May 27, 2021 Filed Jun 1, 2021 21:10 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | GiftOrdinary Shares | 4,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001651308-21-000098 · wf-form4_162258182753878.xml · nonDerivative · entry 1 Glazer Donald W. · CIK 0001660940 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,823,129 F1 · price: Bona fide gift of shares which is exempt from Section 16(b) of the Securities Exchange Act pursuant to Rule 16b-5. Read SEC document |
| March 12, 2021 Filed Mar 16, 2021 20:31 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | GiftOrdinary Shares | 80,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001651308-21-000049 · wf-form4_161592667190254.xml · nonDerivative · entry 1 Glazer Donald W. · CIK 0001660940 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,827,829 F1 · price: Bona fide gift of shares which is exempt from Section 16(b) of the Securities Exchange Act pursuant to Rule 16b-5. Read SEC document |
| December 04, 2020 Filed Dec 8, 2020 21:50 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | GiftOrdinary Shares | 589,849 | $0.00 | $0.00 |
DisclosureSEC source: 0001651308-20-000230 · wf-form4_160746423986620.xml · nonDerivative · entry 1 Glazer Donald W. · CIK 0001660940 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,907,829 F1 · price: Bona fide gifts of shares which are exempt from Section 16(b) of the Securities Exchange Act pursuant to Rule 16b-5. Read SEC document |
| June 17, 2020 Filed Jun 19, 2020 20:20 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | GrantShare Option (Right to Buy) · Derivative | 45,383 | $0.00 Strike: $13.42 | $0.00 |
DisclosureSEC source: 0001651308-20-000080 · wf-form4_159259798774597.xml · derivative · entry 2 Glazer Donald W. · CIK 0001660940 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,383 Underlying: Ordinary Shares · 45,383 shares Expires 2030-06-16 F1 · derivative.exercise_price: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. Each American Depositary Share represents 13 Ordinary Shares. F1 · shares: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. Each American Depositary Share represents 13 Ordinary Shares. F2 · derivative.exercise_date: The option shall become exercisable in full upon the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting; provided, however, that all vesting shall cease if the Reporting Person resigns from the board of directors or otherwise ceases to serve as a director, unless the board determines otherwise. Unvested securities are subject to accelerated vesting upon a change in control or certain termination events. Read SEC document |
| May 19, 2020 Filed May 21, 2020 20:08 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 10,000 | $169.84 | $1,698,400.00 |
DisclosureSEC source: 0001651308-20-000058 · wf-form4_159009168711042.xml · nonDerivative · entry 2 Glazer Donald W. · CIK 0001660940 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F2 · security: Each American Depositary Share represents 13 Ordinary Shares. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $169.53 to $170.08, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| May 19, 2020 Filed May 21, 2020 20:08 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | GiftOrdinary Shares | 2,680 | $0.00 | $0.00 |
DisclosureSEC source: 0001651308-20-000058 · wf-form4_159009168711042.xml · nonDerivative · entry 1 Glazer Donald W. · CIK 0001660940 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,497,678 F1 · shares: Bona fide gifts of shares which are exempt from Section 16(b) of the Exchange Act pursuant to Rule 16b-5. Read SEC document |
| November 20, 2019 Filed Nov 22, 2019 21:00 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | GiftOrdinary Shares | 81,060 | $0.00 | $0.00 |
DisclosureSEC source: 0001651308-19-000120 · wf-form4_157445640632379.xml · nonDerivative · entry 1 Glazer Donald W. · CIK 0001660940 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,630,366 F1 · shares: Bona fide gifts of shares which are exempt from Section 16(b) of the Exchange Act pursuant to Rule 16b-5. Read SEC document |
| August 12, 2019 Filed Aug 14, 2019 20:08 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | OtherOrdinary Shares | 26,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001651308-19-000081 · wf-form4_156581328904245.xml · nonDerivative · entry 2 Glazer Donald W. · CIK 0001660940 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,711,426 F3 · shares: The reporting person transferred these ordinary shares to his spouse pursuant to a divorce decree effective at a future date. The reporting person no longer reports as beneficially owned any securities owned by his spouse. Read SEC document |
| August 12, 2019 Filed Aug 14, 2019 20:08 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | OtherAmerican Depositary Shares | 13,384 | $0.00 | $0.00 |
DisclosureSEC source: 0001651308-19-000081 · wf-form4_156581328904245.xml · nonDerivative · entry 1 Glazer Donald W. · CIK 0001660940 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F2 · shares: The reporting person transferred these American Depositary Shares to his spouse pursuant to a divorce decree effective at a future date. Read SEC document |
| June 05, 2019 Filed Jun 7, 2019 20:08 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | GrantShare Option (Right to Buy) · Derivative | 64,610 | $0.00 Strike: $9.23 | $0.00 |
DisclosureSEC source: 0001651308-19-000055 · wf-form4_155993809255577.xml · derivative · entry 1 Glazer Donald W. · CIK 0001660940 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,610 Underlying: Ordinary Shares · 64,610 shares Expires 2029-06-04 F1 · derivative.exercise_price: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. Each American Depositary Share represents 13 ordinary shares. F1 · shares: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. Each American Depositary Share represents 13 ordinary shares. F2 · derivative.exercise_date: The option shall become exercisable in full upon the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting; provided, however, that all vesting shall cease if the Reporting Person resigns from the board of directors or otherwise ceases to serve as a director, unless the board determines otherwise. Unvested securities are subject to accelerated vesting upon a change in control or certain termination events. F1 · derivative.underlying_shares: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. Each American Depositary Share represents 13 ordinary shares. Read SEC document |
| May 13, 2019 Filed May 15, 2019 19:59 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 15,027 | $125.11 | $1,880,027.97 |
DisclosureSEC source: 0001651308-19-000046 · wf-form4_155795038114805.xml · nonDerivative · entry 2 Glazer Donald W. · CIK 0001660940 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F2 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $125.00 to $125.63, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depository Shares, sold at each separate price. Read SEC document |
| March 14, 2019 Filed Mar 18, 2019 22:30 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 14,973 | $136.10 | $2,037,825.30 |
DisclosureSEC source: 0001651308-19-000027 · wf-form4_155294821804203.xml · nonDerivative · entry 2 Glazer Donald W. · CIK 0001660940 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $136.00 to $136.88, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depository Shares, sold at each separate price. Read SEC document |
| November 19, 2018 Filed Nov 21, 2018 23:42 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | GiftOrdinary Shares | 3,138 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-18-069636 · a4.xml · nonDerivative · entry 3 Glazer Donald W. · CIK 0001660940 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,127,526 F1 · price: Bona fide gift of shares which is exempt from Section 16(b) of the Exchange Act pursuant to Rule 16b-5. Read SEC document |
| November 19, 2018 Filed Nov 21, 2018 23:42 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | GiftOrdinary Shares | 3,138 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-18-069636 · a4.xml · nonDerivative · entry 2 Glazer Donald W. · CIK 0001660940 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,130,664 F1 · price: Bona fide gift of shares which is exempt from Section 16(b) of the Exchange Act pursuant to Rule 16b-5. Read SEC document |
| November 19, 2018 Filed Nov 21, 2018 23:42 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | GiftOrdinary Shares | 3,138 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-18-069636 · a4.xml · nonDerivative · entry 1 Glazer Donald W. · CIK 0001660940 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,133,802 F1 · price: Bona fide gift of shares which is exempt from Section 16(b) of the Exchange Act pursuant to Rule 16b-5. Read SEC document |
| August 30, 2018 Filed Aug 31, 2018 20:54 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 1,000 | $179.00 | $179,000.00 |
DisclosureSEC source: 0001179110-18-011044 · edgar.xml · nonDerivative · entry 2 Glazer Donald W. · CIK 0001660940 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,384 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. Read SEC document |
| August 29, 2018 Filed Aug 31, 2018 20:54 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 1,000 | $179.00 | $179,000.00 |
DisclosureSEC source: 0001179110-18-011044 · edgar.xml · nonDerivative · entry 1 Glazer Donald W. · CIK 0001660940 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,384 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. Read SEC document |
| June 06, 2018 Filed Jun 8, 2018 21:51 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | GrantShare Option (Right to Buy) · Derivative | 17,442 | $0.00 Strike: $16.15 | $0.00 |
DisclosureSEC source: 0001104659-18-039249 · a4.xml · derivative · entry 5 Glazer Donald W. · CIK 0001660940 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,442 Underlying: Ordinary Shares · 17,442 shares Expires 2028-06-05 F4 · derivative.exercise_price: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. The exercise price is equal to 1/13 of the closing price of our American Depositary Shares ("ADSs") on the date of grant, as each ADS represents 13 ordinary shares. F4 · shares: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. The exercise price is equal to 1/13 of the closing price of our American Depositary Shares ("ADSs") on the date of grant, as each ADS represents 13 ordinary shares. F5 · derivative.exercise_date: The option shall become exercisable in full upon the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting; provided, however, that all vesting shall cease if the Reporting Person resigns from the board of directors or otherwise ceases to serve as a director, unless the board determines otherwise. Unvested securities are subject to accelerated vesting upon a change in control or certain termination events. F4 · derivative.underlying_shares: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. The exercise price is equal to 1/13 of the closing price of our American Depositary Shares ("ADSs") on the date of grant, as each ADS represents 13 ordinary shares. F4 · balance_after: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. The exercise price is equal to 1/13 of the closing price of our American Depositary Shares ("ADSs") on the date of grant, as each ADS represents 13 ordinary shares. Read SEC document |
| June 06, 2018 Filed Jun 8, 2018 21:51 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | GrantOrdinary Shares | 9,290 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-18-039249 · a4.xml · nonDerivative · entry 3 Glazer Donald W. · CIK 0001660940 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,336,932 F3 · security: Represents securities underlying restricted share units ("RSUs"). All securities will vest upon the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting; provided, however, that all vesting shall cease if the Reporting Person resigns from the board of directors or otherwise ceases to serve as a director, unless the board determines otherwise. Unvested securities are subject to accelerated vesting upon a change in control or certain termination events. Read SEC document |
| March 13, 2018 Filed Jun 8, 2018 21:51 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | GiftOrdinary Shares | 199,992 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-18-039249 · a4.xml · nonDerivative · entry 2 Glazer Donald W. · CIK 0001660940 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,327,642 F2 · price: Bona fide gift of shares which is exempt from Section 16(b) of the Securities Exchange Act pursuant to Rule 16b-5. Read SEC document |
| January 26, 2018 Filed Jun 8, 2018 21:51 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | GiftOrdinary Shares | 10,873 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-18-039249 · a4.xml · nonDerivative · entry 1 Glazer Donald W. · CIK 0001660940 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,527,634 F1 · price: This transaction involved a gift of 10,873 ordinary shares by the Reporting Person to his wife, who shares the Reporting Person's household. Read SEC document |
| July 31, 2017 Filed Feb 13, 2018 21:27 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | GiftOrdinary Shares | 27,287 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-002004 · edgar.xml · nonDerivative · entry 1 Glazer Donald W. · CIK 0001660940 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,538,507 F1 · shares: This transaction involved a gift of 27,287 ordinary shares by the Reporting Person to his wife, who shares the Reporting Person's household. The Reporting Person disclaims beneficial ownership of the shares held by his wife, and this report should not be deemed an admission that the Reporting Person is the beneficial owner of his wife's shares for purposes of Section 16 or for any other purpose. Read SEC document |
| July 11, 2017 Filed Jul 13, 2017 01:37 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | GiftOrdinary Shares | 175,682 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-17-044733 · a4.xml · nonDerivative · entry 3 Glazer Donald W. · CIK 0001660940 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,565,794 F4 · price: Bona fide gift of shares which is exempt from Section 16(b) of the Securities Exchange Act pursuant to Rule 16b-5. Read SEC document |
| July 10, 2017 Filed Jul 13, 2017 01:37 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 7,206 | $72.36 | $521,449.94 |
DisclosureSEC source: 0001104659-17-044733 · a4.xml · nonDerivative · entry 2 Glazer Donald W. · CIK 0001660940 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · security: Each American Depositary Share represents 13 ordinary shares. F3 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $72.11 to $72.60, inclusive. The Reporting Person has provided the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| July 10, 2017 Filed Jul 13, 2017 01:37 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 3,604 | $71.71 | $258,449.69 |
DisclosureSEC source: 0001104659-17-044733 · a4.xml · nonDerivative · entry 1 Glazer Donald W. · CIK 0001660940 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,206 F1 · security: Each American Depositary Share represents 13 ordinary shares. F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $71.00 to $71.97, inclusive. The Reporting Person has provided the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| April 19, 2017 Filed Apr 21, 2017 20:43 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | GrantShare Option (Right to Buy) · Derivative | 199,992 | $0.00 Strike: $2.84 | $0.00 |
DisclosureSEC source: 0001179110-17-006145 · edgar.xml · derivative · entry 1 Glazer Donald W. · CIK 0001660940 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 199,992 Underlying: Ordinary Shares · 199,992 shares Expires 2027-04-18 F2 · derivative.exercise_price: In ordinary shares. One American Depositary Share represents 13 ordinary shares. F2 · shares: In ordinary shares. One American Depositary Share represents 13 ordinary shares. F1 · derivative.exercise_date: The option shall become exercisable in equal installments on the first, second and third anniversary of the grant date and shall become exercisable in full on the date of the third annual meeting of shareholders following the grant date. All vesting shall cease if the reporting person resigns from the board or otherwise ceases to serve as a director, unless the board determines that the circumstances warrant the continuation of vesting. F2 · derivative.underlying_shares: In ordinary shares. One American Depositary Share represents 13 ordinary shares. F2 · balance_after: In ordinary shares. One American Depositary Share represents 13 ordinary shares. Read SEC document |
| September 28, 2016 Filed Sep 30, 2016 20:50 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares (each represent 13 Ordinary Shar) | 11,300 | $31.16 | $352,108.00 |
DisclosureSEC source: 0001179110-16-030099 · edgar.xml · nonDerivative · entry 2 Glazer Donald W. · CIK 0001660940 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F4 · price: The price reported in column 4 is a weighted average price. These American Depositary Shares were sold in multiple transactions at prices ranging from $31.01 to $31.33, inclusive. The Reporting Person has provided the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price within the range. F3 · ownership.nature: These American Depositary Shares are held for the benefit of the Reporting Person in a Roth IRA account at Fidelity Management Trust Company. Read SEC document |
| September 28, 2016 Filed Sep 30, 2016 20:50 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares (each represent 13 Ordinary Shar) | 30,163 | $30.47 | $919,066.61 |
DisclosureSEC source: 0001179110-16-030099 · edgar.xml · nonDerivative · entry 1 Glazer Donald W. · CIK 0001660940 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 11,300 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The price reported in column 4 is a weighted average price. These American Depositary Shares were sold in multiple transactions at prices ranging from $30.00 to $31.00, inclusive. The Reporting Person has provided the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price within the range. F3 · ownership.nature: These American Depositary Shares are held for the benefit of the Reporting Person in a Roth IRA account at Fidelity Management Trust Company. Read SEC document |
| September 27, 2016 Filed Sep 28, 2016 20:11 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares (each represent 13 Ordinary Shar) | 26,483 | $29.63 | $784,691.29 |
DisclosureSEC source: 0001179110-16-030068 · edgar.xml · nonDerivative · entry 2 Glazer Donald W. · CIK 0001660940 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 41,463 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F4 · price: The price reported in column 4 is a weighted average price. These American Depositary Shares were sold in multiple transactions at prices ranging from $29.50 to $30.41, inclusive. The Reporting Person has provided the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price within the range. F3 · ownership.nature: These American Depositary Shares are held for the benefit of the Reporting Person in a Roth IRA account at Fidelity Management Trust Company. Read SEC document |
| September 26, 2016 Filed Sep 28, 2016 20:11 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares (each represent 13 Ordinary Shar) | 20,666 | $29.58 | $611,300.28 |
DisclosureSEC source: 0001179110-16-030068 · edgar.xml · nonDerivative · entry 1 Glazer Donald W. · CIK 0001660940 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 67,946 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The price reported in column 4 is a weighted average price. These American Depositary Shares were sold in multiple transactions at prices ranging from $29.50 to $30.32, inclusive. The Reporting Person has provided the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price within the range. F3 · ownership.nature: These American Depositary Shares are held for the benefit of the Reporting Person in a Roth IRA account at Fidelity Management Trust Company. Read SEC document |
| September 23, 2016 Filed Sep 26, 2016 22:12 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares (each represent 13 Ordinary Shar) | 11,433 | $30.77 | $351,793.41 |
DisclosureSEC source: 0001179110-16-030037 · edgar.xml · nonDerivative · entry 2 Glazer Donald W. · CIK 0001660940 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 88,612 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F4 · price: The price reported in column 4 is a weighted average price. These American Depositary Shares were sold in multiple transactions at prices ranging from $30.50 to $31.44, inclusive. The Reporting Person has provided the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price within the range. F3 · ownership.nature: These American Depositary Shares are held for the benefit of the Reporting Person in a Roth IRA account at Fidelity Management Trust Company. Read SEC document |
| September 22, 2016 Filed Sep 26, 2016 22:12 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares (each represent 13 Ordinary Shar) | 25,010 | $31.13 | $778,561.30 |
DisclosureSEC source: 0001179110-16-030037 · edgar.xml · nonDerivative · entry 1 Glazer Donald W. · CIK 0001660940 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 100,045 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The price reported in column 4 is a weighted average price. These American Depositary Shares were sold in multiple transactions at prices ranging from $31.00 to $31.43, inclusive. The Reporting Person has provided the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price within the range. F3 · ownership.nature: These American Depositary Shares are held for the benefit of the Reporting Person in a Roth IRA account at Fidelity Management Trust Company. Read SEC document |
| September 21, 2016 Filed Sep 22, 2016 01:11 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares (each represent 13 Ordinary Shar) | 16,318 | $31.19 | $508,958.42 |
DisclosureSEC source: 0001179110-16-029921 · edgar.xml · nonDerivative · entry 4 Glazer Donald W. · CIK 0001660940 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 125,055 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F6 · price: The price reported in column 4 is a weighted average price. These American Depositary Shares were sold in multiple transactions at prices ranging from $31.00 to $31.50, inclusive. The Reporting Person has provided the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price within the range. F3 · ownership.nature: These American Depositary Shares are held for the benefit of the Reporting Person in a Roth IRA account at Fidelity Management Trust Company. Read SEC document |
| September 20, 2016 Filed Sep 22, 2016 01:11 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares (each represent 13 Ordinary Shar) | 8,243 | $31.01 | $255,615.43 |
DisclosureSEC source: 0001179110-16-029921 · edgar.xml · nonDerivative · entry 3 Glazer Donald W. · CIK 0001660940 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 141,373 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F5 · price: The price reported in column 4 is a weighted average price. These American Depositary Shares were sold in multiple transactions at prices ranging from $31.00 to $31.13, inclusive. The Reporting Person has provided the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price within the range. F3 · ownership.nature: These American Depositary Shares are held for the benefit of the Reporting Person in a Roth IRA account at Fidelity Management Trust Company. Read SEC document |
| September 19, 2016 Filed Sep 22, 2016 01:11 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares (each represent 13 Ordinary Shar) | 1,900 | $32.17 | $61,123.00 |
DisclosureSEC source: 0001179110-16-029921 · edgar.xml · nonDerivative · entry 2 Glazer Donald W. · CIK 0001660940 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 149,616 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F4 · price: The price reported in column 4 is a weighted average price. These American Depositary Shares were sold in multiple transactions at prices ranging from $32.01 to $32.30, inclusive. The Reporting Person has provided the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price within the range. F3 · ownership.nature: These American Depositary Shares are held for the benefit of the Reporting Person in a Roth IRA account at Fidelity Management Trust Company. Read SEC document |
| September 19, 2016 Filed Sep 22, 2016 01:11 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares (each represent 13 Ordinary Shar) | 40,791 | $31.56 | $1,287,363.96 |
DisclosureSEC source: 0001179110-16-029921 · edgar.xml · nonDerivative · entry 1 Glazer Donald W. · CIK 0001660940 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 151,516 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The price reported in column 4 is a weighted average price. These American Depositary Shares were sold in multiple transactions at prices ranging from $31.00 to $32.00, inclusive. The Reporting Person has provided the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price within the range. F3 · ownership.nature: These American Depositary Shares are held for the benefit of the Reporting Person in a Roth IRA account at Fidelity Management Trust Company. Read SEC document |
| July 14, 2016 Filed Sep 22, 2016 01:11 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | GiftOrdinary Shares | 3 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-16-029921 · edgar.xml · nonDerivative · entry 7 Glazer Donald W. · CIK 0001660940 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,881,997 F9 · price: Bona fide gift of shares which is exempt from Section 16(b) of the Exchange Act pursuant to Rule 16b-5. Read SEC document |
| July 07, 2016 Filed Sep 22, 2016 01:11 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | GiftOrdinary Shares | 250,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-16-029921 · edgar.xml · nonDerivative · entry 6 Glazer Donald W. · CIK 0001660940 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,882,000 F8 · price: Bona fide gift of shares which is exempt from Section 16(b) of the Exchange Act pursuant to Rule 16b-5. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.